Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654745 · ClinicalTrials.gov registry record · Phase 4
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
A Phase 4 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 207
- Enrollment target
NCT00654745 is a Phase 4 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 207 participants.
The verdict
NCT00654745, a Phase 4 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 207 participants
- Enrollment target
Study Summary
To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
Interventions
- DRUG Amlodipine
- DRUG Hydrochlorothiazide
- DRUG amlodipine / olmesartan medoxomil combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654745
The ClinicalTrials.gov registry entry for NCT00654745 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Amlodipine is the first listed.
NCT00654745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654745 about?
NCT00654745 is a clinical study titled "18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics". To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
What is the current status of trial NCT00654745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 207 participants. The study started on 2008-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00654745?
The interventions under investigation include: Amlodipine (DRUG), Hydrochlorothiazide (DRUG), amlodipine / olmesartan medoxomil combination (DRUG).
Who is sponsoring clinical trial NCT00654745?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.